The binding of therapeutic antibodies to CD64 is of particular interest, as CD64+ myeloid cells producing IL-23 are increased in the inflamed colon in IBD, and this binding might potentially enhance IL-23 blockade. The gene discussed is IL37; the disease is inflammatory bowel disease.